Alirocumab is a fully human PCSK9 inhibitor antibody approved by the FDA as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular (CV) disease, who require additional lowering of LDL-C. Here, PCSK9 is linked to familial hypercholesterolemia.